Abstract
Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1140-1143 |
| Number of pages | 4 |
| Journal | Neurology |
| Volume | 27 |
| Issue number | 12 |
| State | Published - 1977 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Arts and Humanities (miscellaneous)
- Clinical Neurology
- Neuroscience(all)
Cite this
Experiences with a new ergoline (CF 25-397) in parkinsonism. / Teychenne, Paul F.; Pfeiffer, Ronald; Bern, Stanley M.; Calne, Donald B.
In: Neurology, Vol. 27, No. 12, 1977, p. 1140-1143.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Experiences with a new ergoline (CF 25-397) in parkinsonism
AU - Teychenne, Paul F.
AU - Pfeiffer, Ronald
AU - Bern, Stanley M.
AU - Calne, Donald B.
PY - 1977
Y1 - 1977
N2 - Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution.
AB - Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution.
UR - http://www.scopus.com/inward/record.url?scp=0017573688&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017573688&partnerID=8YFLogxK
M3 - Article
C2 - 563012
AN - SCOPUS:0017573688
VL - 27
SP - 1140
EP - 1143
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 12
ER -